President and CEO, EBR Systems
Stories naming John McCutcheon. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cardiac device maker EBR Systems has won US regulator clearance for its leadless heart-failure therapy, clearing the way for staged commercial release later in 2025 and broader distribution in 2026.
EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
US-based leadless pacemaker maker EBR Systems has listed on the ASX, spurning US SPAC offers thanks to its local investor base; Blackbird's earlier investment in Vexev is also noted.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio
A French cardiac specialist performed the first leadless left bundle branch area pacing implant using EBR Systems' wireless pacing device, with the announcement recalling the company's private equity backers.
EBR Systems' wireless cardiac pacing system won FDA Breakthrough Device Designation, bringing priority review, while its SOLVE CRT pivotal trial enrolls heart failure patients; the company counts Brandon Capital among its backers.
Cardiac pacing developer EBR Systems has completed a $30 million financing co-led by two Australian investors to finish its clinical trial, and has appointed John McCutcheon as president and chief executive.